EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical development of a novel Group B Streptococcus ( GBS ) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp)

Christopher Banks iD, Bengt J Lindbom, Geoff Kitson, Michael Darsley, Per B Fischer

Birth Defects Research · 2023

DOI: 10.1002/bdr2.2173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Birth Defects Research, 2023. Verfasst von Christopher Banks und 4 weiteren Autor:innen. Beteiligte Einrichtung: LeyshonBanks Toxicology and Management, Castelnau-Magnoacc, 65230, France. Hauptthemen laut MEDLINE: Membrane Proteins, Vaccines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel Group B Streptococcus (GBS) vaccine, based upon the GBS alpha‐like surface proteins, is being developed by MinervaX for administration to pregnant women. The vaccine is intended to generate antibodies (IgG) capable of crossing the placenta, in order to passively immunize the baby and provide protection in utero and up to 3 months after birth. An initial vaccine candidate, GBS‐NN (based on the N‐terminal domains of Rib and AlphaC surface proteins) was replaced, due to insufficient cross‐reactivity with the two other N‐terminal proteins (Alp1 and Alp2/3), by a modified vaccine candidate designated GBS‐NN/NN2 that included all four AlpNs. Preclinical studies raised no safety concerns and the subsequent Phase I clinical trial demonstrated that the vaccine was well tolerated and strongly immunogenic. As the vaccine is intended for use during pregnancy for maternal immunization, an embryofetal study in rats and a fertility and embryofetal study in rabbits were performed, in both cases using GBS‐NN/NN2. Vaccination of female rats or rabbits did not adversely affect embryofetal development or survival in either species, or mating or fertility in rabbits. In both studies, the pregnant animals developed immune responses to GBS‐NN and GBS‐NN2 proteins and concentrations of antibodies to both fusion proteins were detected in the fetuses and in the amniotic fluid. Data generated during these reproductive studies indicated a suitable safety margin (approximately 40‐fold clinical dose) considered appropriate to support a subsequent human trial of GBS‐NN/NN2 administered in the second and third trimesters of pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsVaccinesAnimalsFemalePregnancyRabbitsRatsAntibodies, BacterialImmunizationStreptococcus agalactiaeVaccinationClinical Trials, Phase I as TopicHumans

Stichwörter der Autor:innen

GBS-NN/NN2embryofetalfertilitymaternal immunizationrabbitratvaccine

Substanzen

Antibodies, BacterialMembrane ProteinsVaccines

Autor:innen und Institutionen

  • LeyshonBanks Toxicology and Management, Castelnau-Magnoacc, 65230, France.
  • Minervax ApS, DK-2200, Copenhagen N, Denmark.
  • Propharma Partners International, Horsham, RH12 1SL, UK.
  • MD Biologic Consulting Ltd, Babraham, Cambridge, CB22 3GN, UK.

ORCID-Profile: Christopher Banks

Zitieren

APA

Banks, C., Lindbom, B. J., Kitson, G., Darsley, M., & Fischer, P. B. (2023). Preclinical development of a novel Group B Streptococcus ( GBS ) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp). Birth Defects Research. https://doi.org/10.1002/bdr2.2173

Vancouver

Banks C, Lindbom BJ, Kitson G, Darsley M, Fischer PB. Preclinical development of a novel Group B Streptococcus ( GBS ) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp). Birth Defects Research. 2023. doi:10.1002/bdr2.2173

BibTeX
@article{Banks2023,
  author = {Banks, Christopher and Lindbom, Bengt J and Kitson, Geoff and Darsley, Michael and Fischer, Per B},
  title = {Preclinical development of a novel Group B Streptococcus ( GBS ) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp)},
  journal = {Birth Defects Research},
  year = {2023},
  doi = {10.1002/bdr2.2173}
}
Kostenlos starten →